Clinical ResearchMyocardial InfarctionPrognostic Value of Midregional Pro-Adrenomedullin in Patients With Acute Myocardial Infarction: The LAMP (Leicester Acute Myocardial Infarction Peptide) Study
Myocardial Infarction
Under an Elsevier user license
open archive
Abbreviations and Acronyms
ADM
adrenomedullin
AMI
acute myocardial infarction
HF
heart failure
MR-proADM
midregional pro-adrenomedullin
NSTEMI
non–ST-segment elevation myocardial infarction
NTproBNP
N-terminal pro-B-type natriuretic peptide
STEMI
ST-segment elevation myocardial infarction
Cited by (0)
- 1
Dr. Khan is supported by a British Heart Foundation Junior Research Fellowship (FS/03/028/15486). BRAHMS AG is a midsized company based in Hennigsdorf, Germany; it commercializes immunoassays, and has developed the MR-proADM assay, for which it owns patent rights.
- 2
Dr. Bergmann holds ownership in BRAHMS AG and patent rights to the markers of the study, and is a member of the board of directors of BRAHMS AG.
- 3
Dr. Struck holds patent rights to the markers and is an employee of BRAHMS AG.
- 4
Dr. Morgenthaler is an employee of BRAHMS AG.
Copyright © 2007 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.